dt-7012
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 25, 2025 (NCT06819735)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- C-C chemokine receptor type 8INHIBITOR
CCR8 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07213882 | Early Phase 1 (Phase 1) | Jan 1, 2026 | Assistance Publique - Hôpitaux de Paris, Domain Therapeutics SA |
| NCT06819735 | Phase 1/Phase 2 (Phase 2) | Jun 25, 2025 | Domain Therapeutics Australia Pty Ltd, Domain Therapeutics SA |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Domain Therapeutics SA | For profit | 2 | 0 | 2 | 2025 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Domain Therapeutics Australia Pty Ltd | For profit | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1